Repository logo
  • English
  • Italiano
Log In
New user? Click here to register.Have you forgotten your password?
Repository logo
  • English
  • Italiano
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. ASI Community
  3. ASI Multidisciplinary Collection
  4. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
 
  • Details

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.

Author(s)
ASI Sponsor
Arlot-Bonnemains, Yannick
Baldini, Enke
Martin, Benedicte
Subjects

Agar

Apoptosis

Apoptosis: drug effec...

Cell Cycle

Cell Cycle: drug effe...

Cell Division

Cell Division: drug e...

Cell Line

Enzyme Inhibitors

Enzyme Inhibitors: ph...

Histones

Histones: metabolism

Humans

Microtubule-Associate...

Microtubule-Associate...

Phosphorylation

Phosphorylation: drug...

Piperazines

Piperazines: pharmaco...

Ploidies

Protein-Serine-Threon...

Protein-Serine-Threon...

Protein-Serine-Threon...

Thyroid Gland

Thyroid Gland: cytolo...

Thyroid Neoplasms

Thyroid Neoplasms: dr...

Thyroid Neoplasms: pa...

Tumor

Date Issued
2008-06-01
Abstract
Anaplastic thyroid cancers (ATC) are aggressive tumors, which exhibit cell cycle misregulations leading to uncontrolled cellular proliferation and genomic instability. They fail to respond to chemotherapeutic agents and radiation therapy, and most patients die within a few months of diagnosis. In the present study, we evaluated the in vitro effects on ATC cells of VX-680, an inhibitor of the Aurora serine/threonine kinases involved in the regulation of multiple aspects of chromosome segregation and cytokinesis. The effects of VX-680 on proliferation, apoptosis, soft agar colony formation, cell cycle, and ploidy were tested on the ATC-derived cell lines CAL-62, 8305C, 8505C, and BHT-101. Treatment of the different ATC cells with VX-680 inhibited proliferation in a time- and dose-dependent manner, with the IC50 between 25 and 150 nM. The VX-680 significantly impaired the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity showed that VX-680 induced apoptosis in the different cell lines. CAL-62 cells exposed for 12 h to VX-680 showed an accumulation of cells with > or =4N DNA content. Time-lapse analysis demonstrated that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation was abrogated following VX-680 treatment. In conclusion, our data demonstrated that VX-680 is effective in reducing cell growth of different ATC-derived cell lines and warrant further investigation to exploit its potential therapeutic value for ATC treatment.
URI
https://hdl.handle.net/20.500.13025/2326
ISSN
1351-0088
Journal
Endocrine-related cancer
URL
http://erc.endocrinology-journals.org/cgi/content/abstract/15/2/559
http://www.ncbi.nlm.nih.gov/pubmed/18430894
Explore by
  • Communities & Collections
  • Research Outputs

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback